Sarepta Therapeutics (SRPT)
$90.32 0.42 (0.47%)
19:59 EST SRPT Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 5.92B
PE Ratio -30.72
Volume (Avg. Vol.) 3.40M
Day's Range 89.41 - 92.79
52-Week Range 78.06 - 181.83
Dividend & Yield N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
- From InvestorPlace
- From the Web
Shares of SRPT stock are getting hammered on Friday after Sarepta Therapeutics reported negative results from a treatment trial.
Sarepta Therapeutics (SRPT) has good news for SRPT stock investors concerning its treatment for Duchenne muscular dystrophy.
Apple, General Motors, Delta Air Lines, Sarepta and Bristol-Myers Squibb were our top stock trades to watch for Tuesday. Here's what you need to know.
Apple's health initiative can't keep key people and Sarepta Therapeutics' CLR are a couple more top news items about the stock market today.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
If you follow the smart money, you end up following these stocks to buy. Here's what you should know about each.
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.
According to Wall Street, these 7 stellar strong buy stock picks all boast over 30% upside potential from their current prices.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
Navellier RatingsPowered by Portfolio Grader